Crizotinib-induced immunogenic cell death in non-small cell lung cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
Authors
Keywords
-
Journal
Nature Communications
Volume 10, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-04-02
DOI
10.1038/s41467-019-09415-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
- (2018) David R. Spigel et al. Journal of Thoracic Oncology
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- (2018) Marina Chiara Garassino et al. LANCET ONCOLOGY
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves
- (2018) David P. Enot et al. OncoImmunology
- High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair
- (2017) Marco E. Bianchi et al. IMMUNOLOGICAL REVIEWS
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2017) Nasser Hanna et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia
- (2017) Qingsong Yin et al. JOURNAL OF IMMUNOLOGY
- Global survey of the immunomodulatory potential of common drugs
- (2017) Gregory I Vladimer et al. Nature Chemical Biology
- Automating drug discovery
- (2017) Gisbert Schneider NATURE REVIEWS DRUG DISCOVERY
- Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer
- (2017) Courèche-Guillaume Kaderbhai et al. OncoImmunology
- Progress towards a public chemogenomic set for protein kinases and a call for contributions
- (2017) David H. Drewry et al. PLoS One
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
- (2016) Christina Pfirschke et al. IMMUNITY
- The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
- (2016) Chiara Pozzi et al. NATURE MEDICINE
- A causal link from ALK to hexokinase II overexpression and hyperactive glycolysis in EML4-ALK-positive lung cancer
- (2016) Y Ma et al. ONCOGENE
- Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer
- (2016) Gautier Stoll et al. OncoImmunology
- Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy
- (2016) Heng Yang et al. OncoImmunology
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
- (2015) E. Vacchelli et al. SCIENCE
- Discordant Growth of Monozygotic Twins Starts at the Blastocyst Stage: A Case Study
- (2015) Laila Noli et al. Stem Cell Reports
- Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy
- (2014) Kilian V. M. Huber et al. NATURE
- Molecular Pathways: ROS1 Fusion Proteins in Cancer
- (2013) K. D. Davies et al. CLINICAL CANCER RESEARCH
- Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells
- (2013) Yuting Ma et al. IMMUNITY
- ALKin Lung Cancer: Past, Present, and Future
- (2013) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- The secret ally: immunostimulation by anticancer drugs
- (2012) Lorenzo Galluzzi et al. NATURE REVIEWS DRUG DISCOVERY
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Immunosurveillance Mechanism Controls Cancer Cell Ploidy
- (2012) L. Senovilla et al. SCIENCE
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
- (2012) L. Menger et al. Science Translational Medicine
- Induction of Immunogenic Apoptosis by Blockade of Epidermal Growth Factor Receptor Activation with a Specific Antibody
- (2011) Greta Garrido et al. JOURNAL OF IMMUNOLOGY
- Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
- (2011) Nicolas F Delahaye et al. NATURE MEDICINE
- Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
- (2011) Vince D. Cataldo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
- (2011) M. Michaud et al. SCIENCE
- Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death
- (2009) Theocharis Panaretakis et al. EMBO JOURNAL
- Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
- (2009) Michel DuPage et al. Nature Protocols
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now